Endocrine Testing Market By Test Type (Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone Test, Human Chorionic Gonadotropin Hormone Test, Cortisol Test, Insulin Test, and Others), By Technology (Immunoassay, Mass Spectroscopy, Chromatography, and Nucleic Acid Based), By End-user (Hospitals, Commercial Laboratories, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Endocrine Testing Market Size is expected to be worth around USD 6.1 billion by 2033 from USD 2.7 billion in 2023, growing at a CAGR of 8.5% during the forecast period 2024 to 2033. The growing prevalence of endocrine disorders is a significant driver of market growth.

According to a May 2023 article by Springer Nature Limited, thyroid cancer is the most common endocrine cancer, with approximately 11,860 new cases in men and 31,940 in women in the U.S. in 2022. Increasing demand for home healthcare, greater awareness of routine testing, advancements in product technologies, and rising investments in research to better understand these diseases are expected to further boost market growth.

Technological advancements in endocrine testing are also fueling demand. An October 2023 article from the Cureus, Springer Nature Group, highlighted significant progress in treating endocrine system diseases and arrhythmias in recent years. Disorders such as diabetes, thyroid dysfunction, and adrenal gland disease are now being better-diagnosed thanks to advances in biomarker identification and genomic profiling, enabling more personalized treatment plans.

Furthermore, modern drugs and innovative delivery systems have led to improved glycemic control and reduced adverse effects in patients suffering from endocrine disorders and arrhythmias.

Key Takeaways

• In 2023, the market for Endocrine Testing generated a revenue of USD 2.7 billion, with a CAGR of 8.5%, and is expected to reach USD 6.1 billion by the year 2033.
• The test type segment is divided into progesterone test, testosterone test, thyroid stimulating hormone test, human chorionic gonadotropin hormone test, cortisol test, insulin test, and others, with thyroid stimulating hormone test taking the lead in 2023 with a market share of 26.7%.
• Considering technology, the market is divided into immunoassay, mass spectroscopy, chromatography, and nucleic acid-based. Among these, mass spectroscopy held a significant share of 38.2%.
• Furthermore, concerning the end-user segment, the market is segregated into hospitals, commercial laboratories, and others. The hospital sector stands out as the dominant player, holding the largest revenue share of 53.8% in the Endocrine Testing market.
• North America led the market by securing a market share of 40.6% in 2023.

Test Type Analysis

The thyroid stimulating hormone test segment led in 2023, claiming a market share of 26.7% owing to the increasing prevalence of thyroid disorders such as hypothyroidism and hyperthyroidism. Rising awareness of thyroid health, along with the growing aging population, drives demand for regular TSH testing.

Physicians commonly recommend TSH tests as part of routine checkups, further boosting their adoption. Additionally, advancements in testing accuracy and faster results have made TSH tests more accessible and reliable, encouraging more frequent use in clinical settings. The increasing number of thyroid-related diagnoses, along with the emphasis on early detection and management of thyroid disorders, is anticipated to continue driving the growth of the TSH test segment.

Technology Analysis

Mass spectroscopy held a significant share of 38.2% due to its high sensitivity and precision in detecting low-concentration hormones. Mass spectrometry offers superior accuracy compared to traditional immunoassays, making it the preferred method for detecting steroid hormones like testosterone and cortisol.

Researchers and clinicians increasingly turn to mass spectrometry for its ability to provide detailed molecular analysis and resolve complex hormone profiles. Advances in technology, such as the development of more compact and faster mass spectrometry equipment, are expected to further increase its adoption. The rising demand for accurate and specific hormone testing in both clinical diagnostics and research applications is likely to propel growth in this segment.

End-user Analysis

The hospitals segment had a tremendous growth rate, with a revenue share of 53.8% owing to the comprehensive healthcare services hospitals offer, including specialized diagnostic capabilities. Hospitals are typically equipped with advanced technology and highly trained medical staff, making them the preferred choice for patients requiring complex endocrine tests.

The growing incidence of endocrine disorders, such as diabetes and thyroid conditions, drives an increasing number of patients to seek diagnosis and treatment in hospital settings. Hospitals also tend to manage a higher volume of patients compared to commercial laboratories, offering a range of tests that cater to both routine checkups and critical diagnostics. As patient awareness and access to healthcare services improve, hospitals are likely to experience sustained growth in the demand for endocrine testing.

Key Market Segments

By Test Type

• Progesterone Test
• Testosterone Test
• Thyroid Stimulating Hormone Test
• Human Chorionic Gonadotropin Hormone Test
• Cortisol Test
• Insulin Test
• Others

By Technology

• Immunoassay
• Mass Spectroscopy
• Chromatography
• Nucleic Acid Based

By End-user

• Hospitals
• Commercial Laboratories
• Others

Drivers

Growing Prevalence of Obesity

The increasing prevalence of obesity significantly drives the endocrine testing market. Obesity often leads to hormonal imbalances, including conditions like diabetes, thyroid dysfunction, and metabolic disorders, all of which require regular endocrine testing for diagnosis and monitoring.

According to recent data, the WHO estimates that 650 million adults, 340 million adolescents, and 39 million children globally suffer from obesity, and these numbers are growing rapidly. By 2025, overweight and obesity are anticipated to impact the health of 167 million adults and children.

The growing burden of obesity increases the demand for endocrine testing, as healthcare providers aim to manage and monitor the associated complications. Rising awareness about the importance of early detection and the management of obesity-related hormonal issues is expected to further boost the market. As obesity rates continue to climb, endocrine testing will play a crucial role in diagnosing and treating these widespread health challenges.

Restraints

High Costs of Tests

High costs of tests impede the growth of the endocrine testing market. The advanced technology and equipment required for accurate hormone analysis often lead to high testing prices, making it difficult for many patients to afford regular testing. This issue becomes especially prevalent in low-income regions, where healthcare infrastructure may not fully support affordable access to such diagnostic tools.

These high costs also hamper the broader adoption of endocrine testing, even in countries with more developed healthcare systems. The expense associated with specialized tests, like those for cortisol, thyroid, and reproductive hormones, can deter patients from undergoing regular monitoring.

As healthcare budgets tighten, particularly in public health settings, the cost factor is projected to remain a significant restraint on the market, limiting its reach among economically vulnerable populations. Addressing these cost concerns will be essential for unlocking the full potential of the endocrine testing market.

Opportunities

Surge in Global Geriatric Population

Rising global geriatric population presents a significant opportunity for the endocrine testing market. As people age, they become more susceptible to hormone-related disorders, including thyroid imbalances, osteoporosis, and diabetes, all of which require regular monitoring through endocrine testing.

According to the United Nations Population Fund, the global share of people aged 65 and above nearly doubled from 5.5% in 1974 to 10.3% in 2024, and this number is anticipated to double again by 2074, reaching 20.7%. Additionally, the number of people aged 80 and above is projected to more than triple in the same period.

This demographic shift is likely to drive substantial demand for hormone testing as the elderly population seeks treatment for age-related endocrine conditions. The market is expected to expand as healthcare systems prepare to address the growing needs of aging populations, with a particular focus on personalized and preventive healthcare solutions.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors have a substantial influence on the endocrine testing market. Economic downturns or limited healthcare budgets in some countries reduce funding for diagnostic tests, impacting the affordability and accessibility of endocrine-related diagnostics. Rising costs of raw materials and equipment, driven by inflation and global supply chain disruptions, can make these tests more expensive.

Geopolitical tensions may further strain the supply chain, delaying the availability of necessary diagnostic technologies. However, on a positive note, the increasing prevalence of endocrine disorders such as diabetes and thyroid conditions has pushed governments to prioritize healthcare spending.

As nations focus on improving healthcare infrastructure, more investments are being directed toward advanced diagnostic tools, stimulating growth in the market. Additionally, the global push for healthcare equity enhances access to testing, particularly in underserved regions.

Latest Trends

Increasing Advancements in Endocrine Testing

Increasing advancements in endocrine testing are a growing trend projected to drive the market forward. Innovations in diagnostic technology, such as high-throughput screening and biomarker identification, enable more accurate and timely diagnoses.

In July 2022, Watchfrog Laboratory validated a new method for detecting endocrine disruptors through Test Guideline n251 (TG n251). This method, approved by the Organisation for Economic Co-operation and Development (OECD), uses the RADAR assay to detect chemicals that interfere with androgenic hormone signaling.

Such advancements highlight the increasing focus on identifying and addressing endocrine-disrupting chemicals, which is expected to further improve testing accuracy and expand applications. The trend of utilizing cutting-edge assays and other technologies enhances the overall efficiency and scope of testing, helping healthcare providers to better monitor endocrine health.

Regional Analysis

North America is leading the Endocrine Testing Market

North America dominated the market with the highest revenue share of 40.6% owing to rising awareness and the increasing prevalence of endocrine disorders, including thyroid cancer. According to recent data from Science Direct, approximately 43,800 new cases of thyroid cancer were expected to be diagnosed in the United States in 2022, with 11,860 in men and 31,940 in women, along with 2,230 thyroid cancer-related deaths.

The high incidence of thyroid cancer in the U.S. has significantly driven demand for thyroid function testing, as early diagnosis and monitoring are crucial for effective treatment. The growing availability of advanced diagnostic tools and the push for routine screenings have further fueled the market. Additionally, technological advancements in diagnostic platforms, along with government initiatives to improve healthcare access, have contributed to the expansion of endocrine testing in the region.

The Asia Pacific region is expected to experience the highest CAGR during the forecast period

In the Asia Pacific region, the endocrine testing market is anticipated to grow steadily during the forecast period. The rising incidence of diabetes, thyroid disorders, and other hormonal imbalances, combined with an increasing focus on preventive healthcare, is expected to drive market expansion. Technological advancements in diagnostic tools, particularly in countries such as China, Japan, and India, will likely facilitate more accurate and timely hormone testing.

The October 2022 launch of initiatives focused on improving healthcare infrastructure and diagnostic capabilities is projected to enhance the market for endocrine testing in the region. Additionally, increasing awareness among patients and healthcare providers about the importance of early detection and treatment of endocrine disorders will further fuel market demand. The rising investments in healthcare, along with government support, are likely to solidify Asia Pacific’s position as a key market for endocrine testing.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The major players in the Endocrine Testing market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the endocrine testing market focus on developing advanced diagnostic technologies to improve test accuracy and efficiency.

They invest in research and development to create innovative assays and automated systems for faster and more precise hormone analysis. Strategic collaborations with healthcare providers and laboratories expand their market reach and enhance service delivery.

Companies also work on increasing awareness about endocrine disorders and the importance of early diagnosis through educational campaigns. Additionally, expanding their product portfolios to include comprehensive testing panels supports market growth and competitiveness.

Top Key Players in the Endocrine Testing Market

• Siemens Healthineers
• Hoffmann-La Roche Ltd.
• Eli Lilly
• DiaSorin S.p.A.
• Bio-Rad Laboratories Inc.
• bioMerieux SA
• Agilent Technologies Inc.
• Abbott Laboratories
• AB Sciex

Recent Developments

• In November 2023: The FDA approved Eli Lilly’s Zepbound (tirzepatide) injection as the first obesity treatment activating both GIP and GLP-1 hormone receptors. It is indicated for obese or overweight adults and individuals with related medical problems, aiding in weight loss when used with a reduced-calorie diet and increased physical activity.
• In October 2023: Eli Lilly and Company announced results from LIBRETTO-431 and LIBRETTO-531 Phase 3 trials at ESMO Congress 2023. Assessing Retevmo (selpercatinib), LIBRETTO-431 studied its efficacy in RET fusion-positive NSCLC, while LIBRETTO-531 focused on RET-mutant MTC. Compared to chemotherapy and MKIs, respectively, Retevmo showcased promising outcomes in these advanced cancers.
• In April 2023: Eli Health raised USD 3.6 million to improve women’s health with saliva-based continuous hormone monitoring technology. The initial focus of the business will be on the areas, such as menopause, fertility, and general health needs. In later stages, the expansion will include other areas, such as contraception and endocrine diseases, once the necessary additional regulatory and clinical work is completed.
• In March 2021: Abbott Laboratories launched the Alinity m Diagnostics System which offers automation and advanced technology for immunoassay testing. The system provides high throughput and quick turnaround time for endocrine and other diagnostic testing. This launch helped the company to introduce innovative products, further offering a competitive edge.
• In February 2021: Siemens Healthineers introduced the Atellica Solution for Endocrinology, which is a comprehensive, fully automated immunoassay system for endocrine testing. The system enables accurate and reliable results for a wide range of hormones and markers. This product launch helped the company to strengthen its product portfolio across the market.

Report Scope